IN8bio (NASDAQ:INAB – Get Free Report) and Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.
Analyst Recommendations
This is a summary of recent ratings and price targets for IN8bio and Achilles Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IN8bio | 0 | 0 | 3 | 0 | 3.00 |
| Achilles Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
IN8bio presently has a consensus price target of $9.83, suggesting a potential upside of 845.51%. Achilles Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 816.67%. Given IN8bio’s stronger consensus rating and higher probable upside, equities analysts plainly believe IN8bio is more favorable than Achilles Therapeutics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| IN8bio | N/A | -147.67% | -105.00% |
| Achilles Therapeutics | N/A | -42.33% | -37.49% |
Insider & Institutional Ownership
92.1% of IN8bio shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 33.0% of IN8bio shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility and Risk
IN8bio has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.
Valuation & Earnings
This table compares IN8bio and Achilles Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IN8bio | N/A | N/A | -$30.01 million | ($1.01) | -1.03 |
| Achilles Therapeutics | N/A | N/A | -$71.18 million | ($1.89) | -0.63 |
IN8bio is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
IN8bio beats Achilles Therapeutics on 7 of the 11 factors compared between the two stocks.
About IN8bio
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
About Achilles Therapeutics
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
